HARGREAVE HALE AIM VCT PLC
(the “Company”)

Allotment of Shares

The Board announced on 23 January 2026 that the Company had published an offer document (the “Offer Document“) in relation to an offer for subscription of ordinary shares of 1 pence each (the “Ordinary Shares“), to raise up to £20,000,000 with an over-allotment facility to raise up to a further £10,000,000 (the “Offer“). On 1 April 2026, the Company allotted 4,655,078 new Ordinary Shares pursuant to the Offer, conditional only on trading on the London Stock Exchange plc’s main market for listed securities (“Admission“), the timetable for which is set out in more detail below.

The offer price at which the 4,655,078 new Ordinary Shares were allotted was 31.78 pence per Ordinary Share, which was calculated, in accordance with the terms of the Offer, by reference to the last published net asset value per Ordinary Share as at the close of business on 27 March 2026 (as announced on 30 March 2026) divided by 0.965 (to allow for the costs of the Offer).

Application will shortly be made for the 4,655,078 new Ordinary Shares to be admitted to the closed-ended investment funds category of the Official List of the Financial Conduct Authority. It is expected that Admission will occur and dealing will commence in the new Ordinary Shares on or around 2 April 2026. When issued, the new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

As a result of the issue, the total number of Ordinary Shares in issue will be 376,240,655 with each Ordinary Share carrying one vote each. Therefore, the total voting rights in the Company will be 376,240,655. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules. 

The new Ordinary Shares will be issued in registered form and may be held in uncertificated form. Definitive documents of title are expected to be dispatched within 15 business days of allotment. The new Ordinary Shares will be eligible for settlement through CREST with effect from Admission.

Unless the context requires otherwise, terms defined in the Offer Document have the same meaning where used in this announcement.

END

For further information, please contact:

LEI: 213800LRYA19A69SIT31        

Source: Crypto Insider

1.        KEY INFORMATION

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a)        Purchases and sales

(b)        Derivatives transactions (other than option)

(c)        Options transactions in respect of existing securities

(i)        Writing, selling, purchasing or varying

(ii)        Exercising

(d)        Other dealings (including subscribing for new securities)

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

(b)        Agreements, arrangements or understandings relating to options or derivatives

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Crypto Insider

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

(b)        Cash-settled derivative transactions

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

(ii)        Exercise

(d)        Other dealings (including subscribing for new securities)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

(b)        Agreements, arrangements or understandings relating to options or derivatives

(c)        Attachments

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Crypto Insider

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

(b)        Cash-settled derivative transactions

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

(ii)        Exercise

(d)        Other dealings (including subscribing for new securities)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

(b)        Agreements, arrangements or understandings relating to options or derivatives

(c)        Attachments

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Crypto Insider

The paranasal sinus cancer market has shown robust growth, with a size increase from $1.1 billion in 2025 to an expected $1.18 billion in 2026, at a CAGR of 6.7%. Historical growth factors include delayed diagnosis due to nonspecific symptoms, limited access to specialized oncology centers, and reliance on traditional treatment methods.

The market is projected to expand to $1.51 billion by 2030 at a CAGR of 6.5%. Key growth drivers include advancements in targeted therapy and immunotherapy, adoption of AI-supported diagnostic imaging, increased investments in rare cancer research, and the expansion of multidisciplinary cancer care models.

The evolving trends emphasize precision oncology, minimally invasive surgical techniques, and multimodal treatment strategies, contributing to improved early diagnosis and patient-centered cancer care. The surge in oncology research investments, driven by the global cancer burden and demand for innovative therapies, significantly fuels market expansion. For instance, in May 2024, IQVIA noted that global spending on cancer medicines reached $223 billion, with projections to hit $409 billion by 2028, reflecting a substantial rise in investment and interest.

The increase in clinical trials is notably propelling the market’s growth. Advances in medical research and supportive regulatory frameworks drive the prevalence of trials, enhancing therapeutic development and understanding of paranasal sinus cancer. In December 2024, a rise in UK clinical trials from 411 to 426, as reported by the Association of the British Pharmaceutical Industry, exemplifies this trend. Such efforts contribute to improved patient outcomes and lessened treatment side effects.

Market players are prioritizing innovations like perioperative chemo-immunotherapy regimens to secure a competitive edge. This approach uses immune checkpoint inhibitors in conjunction with chemotherapy, aiming for tumor size reduction pre-surgery. For example, Coherus Biosciences initiated a Phase II trial of toripalimab with carboplatin and docetaxel, evidencing a move towards broadening treatment modalities for rare paranasal sinus cancers.

Leading companies in the paranasal sinus cancer market include Bristol-Myers Squibb, Penn Medicine, and more, working across major regions such as North America, which was the largest market in 2025. Asia-Pacific is forecasted as the fastest-growing region. The geographic span includes Australia, China, the USA, among others, reflecting a widespread international market presence.

This report answers key questions about the largest and fastest growing markets for paranasal sinus cancer, its economic relations, and the forces that will shape it, including technological disruptions and regulatory shifts. The study covers market characteristics, size, growth, segmentation, regional and country breakdowns, and competitive landscapes, underpinned by robust forecasts.

Reasons to Purchase:

• Gain a global perspective with extensive coverage across 16 geographies.
• Understand the impact of macro factors like geopolitical conflicts, trade policies, inflation, and interest rate fluctuations.
• Craft regional and country strategies informed by localized data and analysis.
• Identify and invest in high-growth segments.
• Leverage forecast data, trends, and drivers to outpace competitors.
• Segment end-user analysis to better understand customers.
• Benchmark against leading competitors using market share, innovation, and brand strength metrics.
• Estimate market potential through total addressable market (TAM) and market attractiveness scoring.
• Utilize reliable data for internal and external presentations.
• Receive the latest data updates along with an Excel data sheet for easy extraction and analysis.

Markets Covered:

• By Type: Squamous Cell Carcinoma, Adenocarcinoma, Mucoepidermoid Carcinoma, Other Types
• By Diagnosis: Medical History And Physical Examination, Imaging Tests, Biopsy, Other Diagnosis
• By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy
• By End-User: Hospital And Clinics, Cancer Treatment And Research Center, Research Laboratories, Other End-Users

Companies Mentioned: Bristol-Myers Squibb, Penn Medicine, MD Anderson Cancer Center, Mayo Foundation for Medical Education and Research, among others.

Geographies: Australia, Brazil, China, France, Germany, India, Japan, Taiwan, Russia, USA, among others.

Regions: Asia-Pacific, Europe, North America, South America, Middle East, Africa.

Key Attributes

The companies featured in this Paranasal Sinus Cancer market report include:

• Bristol-Myers Squibb
• Penn Medicine
• MD Anderson Cancer Center
• RWJBarnabas Health
• Mayo Foundation for Medical Education and Research
• Stanford Health Care
• Memorial Sloan Kettering Cancer Center
• Massachusetts General Hospital
• The University of Chicago Medical Center
• City of Hope
• Moffitt Cancer Center
• Northwestern Medicine
• UK Markey Cancer Center
• Karmanos Cancer Institute
• Dana-Farber Cancer Institute Inc.
• VCU Massey Cancer Center
• Vanderbilt-Ingram Cancer Center
• Fulgent Pharma
• Duke University Health System

For more information about this report visit https://www.researchandmarkets.com/r/adgxbs

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Paranasal Sinus Cancer Market

Source: Crypto Insider

A Media Snippet accompanying this announcement is available by clicking on this link.

This year’s event drew elite athletes from 35 countries and regions, delivering a spectacular performance of athletic excellence. Both the men’s and women’s competitions witnessed historic breakthroughs: Kenya’s Alex NZIOKA MATATA claimed the men’s title with a time of 00:59:11, while Miriam CHEBET took the women’s gold in 01:06:27. Both athletes shattered the course records and set new all-time bests for half marathons in China, elevating the event’s international stature through world-class competition.

This year marks the 20th anniversary of the Yangzhou Marathon, and more significantly, its inaugural appearance since earning World Athletics’ “Platinum Label” status. As one of only four Platinum Label half marathons in China, this year’s event fully embraces the highest international standards, deploying AI-powered robotic assistants throughout the course to ensure seamless, cutting-edge race operations.

Held during Yangzhou’s legendary “misty March” when spring reaches its peak, the marathon transcends pure competition to become a comprehensive showcase of the city’s allure. The course winds past iconic cultural landmarks such as the Dongguan Ancient Ferry, Wenchang Pavilion, Slender West Lake, and Daming Temple, allowing runners to traverse the Beijing-Hangzhou Grand Canal and immerse themselves in millennia of history. Participants don’t merely race; they journey through the poetic “Yangzhou in March” landscape, experiencing firsthand the profound cultural legacy of this ancient city.

Source: Crypto Insider

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Soleno common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Soleno class action, go to https://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Soleno Phase 3 clinical trial program for diazoxide choline extended-release tablets (“DCCR”) had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (2) as a result, the administration of DCCR to treat hyperphagia in individuals with Prader-Willi syndrome (“PWS”) posed materially greater safety risks than disclosed by Soleno or its executives; and (3) as a result, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Soleno class action, go to https://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        case@rosenlegal.com
        www.rosenlegal.com

Source: Crypto Insider

DeerValley is meeting this demand by spotlighting three DIY-friendly and intuitive models: the DV-1S0442-V3, DV-1S0371-V3, and DV-1S0360-V3. These reliable fixtures reflect a shift toward bathroom hygiene innovation that combines luxury performance with a straightforward installation process.

The DeerValley Philosophy: Built to Belong

At its core, DeerValley approaches product design with a simple mission: to remove the friction from home upgrades. Whether you are a homeowner refreshing fixtures or a professional contractor seeking dependable DeerValley bathroom fixtures, the focus remains on reliable performance and intuitive usability. These are not gadgets designed for the sake of technology; they are modern smart home bathroom solutions built to last.

Flagship Models Designed for the Modern Home

1. Flagship Sanitation Model: DeerValley DV-1S0442-V3 Smart Toilet

The DeerValley DV-1S0442-V3 smart toilet represents the pinnacle of the new collection, specifically designed for those who prioritize a pristine environment. The standout feature is the DeerValley smart toilet with foam shield. This innovative system creates a layer of foam on the water surface that helps reduce splashing and helps contain odors, making it a critical home bathroom tech upgrade. It also incorporates a comprehensive hygienic bidet toilet system with personalized settings for water temperature and pressure.

2. Elevated All-Rounder: DeerValley DV-1S0371-V3 Smart Toilet

For those seeking a balance between high-tech features and sleek design, the DeerValley DV-1S0371-V3 smart toilet is the ideal choice. This model emphasizes the DeerValley bidet toilet experience with an ergonomic design that fits naturally into any residential layout. Like all models in the series, it features touchless bathroom technology, including an automatic foot-sensor-activated lid, reducing physical contact and elevating hygiene standards.

3. Practical Efficiency: DeerValley DV-1S0360-V3 Smart Toilet

The DeerValley DV-1S0360-V3 smart toilet is designed for the practical-minded homeowner seeking a smart toilet with UV sterilization without unnecessary bulk. This model focuses on the core benefits of the brand: smooth installation and dependable long-term performance. The integrated UV sterilization ensures the bidet nozzle remains clean after every use, providing peace of mind for health-conscious families.

Key Lifestyle Benefits

Choosing a DeerValley premium smart toilet is about more than just a bathroom upgrade; it is about reclaiming comfort and prioritizing health:

• Advanced Hygiene: Features like UV sterilization and the foam shield actively fight bacteria and odors.
• Intuitive Usability: From heated seats to soft-closing lids, every feature is designed for daily comfort.
• Installation Ease: True to their Chicago roots, DeerValley ensures their luxury bathroom smart toilet kits are designed for straightforward installation, further enhanced by a built-in water tank that simplifies setup and eliminates water pressure limitations, removing the friction from home renovations.

About DeerValley

Born in Chicago and built for everywhere, DeerValley specializes in creating high-quality, reliable fixtures that fit the lives of real people. From DIYers to professional contractors, DeerValley products are designed to deliver reliable performance and intuitive usability.

For more information on the full range of DeerValley bathroom fixtures, visit the official website at www.deervalleybath.com.

Connect with DeerValley:

Source: Crypto Insider

The study offers distinct new insight into the durability of treatment effect, with symptom stability maintained across 6 months following discontinuation of esketamine NS.

BEERSE, BELGIUM, March 28, 2026 (GLOBE NEWSWIRE) — Johnson & Johnson today announced new data from the ECHO study which support the effectiveness and safety profile of SPRAVATO^® (esketamine NS) and indicate durability of treatment effect across 6 months after treatment discontinuation in a real-world setting for patients with TRD. These data are being presented at this year’s European Psychiatric Association (EPA) Congress, taking place March 28-31, in Prague, Czech Republic.

Key study findings reinforce robust effectiveness of esketamine NS

From across Europe and Israel, 570 patients started the variable treatment period (TP) (mean duration of 9 months) and 301 participants continued into the 6-month post-treatment follow-up (PTFP).¹

Treatment with esketamine NS resulted in significant and meaningful improvements in depressive symptoms, with a mean MADRS^a change from TP baseline to week 4 of –10.3 points (95% CI: −11.1, −9.5; p<0.001), to week 12 of –14.4 points (95% CI: −15.4, −13.5; p<0.001), and to week 48 of −17.6 points (95% CI: −19.4, −15.8; p<0.001).¹

“These results reinforce esketamine nasal spray as an effective option for adults with treatment resistant depression, many of whom have spent too long cycling through treatments that don’t meaningfully improve their symptoms”, said Christine Reif-Leonhard, MD, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt – Goethe University Frankfurt, Frankfurt am Main, Germany.^b “The essential real-world insights gained from the ECHO study complement existing randomised clinical trial findings, further guiding clinical practice and allowing us to optimise personalised treatment pathways for our patients with treatment resistant depression.”

The safety profile was consistent with the established profile of esketamine NS², with no new safety signals identified.^c

The first real-world data to show effect durability after patients stopped treatment

MADRS scores remained stable after stopping esketamine NS with a mean change of –1.4 points from PTFP baseline to week 24.¹ This indicates the durability of effect, as most patients maintained symptom stability with no sign of relapse.

“The ECHO study is unique in that, for the first time, we have evaluated the durability of effect in real world practice after stopping esketamine nasal spray treatment in patients with treatment resistant depression. We were thrilled to see sustained symptom stability across the 6-month follow-up period”, said Tamara Werner-Kiechle, MD, Therapeutic Area Head, Neuroscience, Cardiopulmonary and Early Portfolio, Europe, Middle East & Africa, Johnson & Johnson. “Creating respite from severe depressive symptoms that lasts beyond the immediate treatment period will significantly improve the lives of people affected, both directly and indirectly, by this devastating disease.”

Understanding the important real-world context

Real-world treatment with esketamine NS presented variability in treatment exposure, reflecting individualised clinical decision-making and patient preferences.

The mean treatment duration in the ECHO study was around 9 months with esketamine NS 84 mg being the highest dose taken in 79.3% of patients and the most frequently administered dose in 67.4% of patients.¹

The real-world patient cohort was clinically complex with high severity and chronic TRD (>3-year episodes, mean MADRS 33.3), treatment resistance (mean of 3.8 prior treatment failures in the current episode), and 45.6% of patients had substantial psychiatric comorbidities.¹

Around 47% of ECHO study participants were not working, underlining the severity of illness observed and the real-world implications this can have.¹

Editor’s Notes:

1. The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item, clinician-rated scale used to measure the severity of depressive symptoms in patients with mood disorders.³
2. Dr. Christine Reif-Leonhard has provided consulting and advisory services to Johnson & Johnson. She has been remunerated for the media work.
3. Treatment-emergent adverse events (TEAEs) were observed in 81.4% of patients, and 7.7% experienced an adverse event which led to treatment discontinuation. 34.9% of patients reported TEAEs with a maximum severity of mild. The most commonly reported TEAEs were dissociation (35.1%), dizziness (33.5%) and increased blood pressure (21.4%).¹

ABOUT THE ECHO RWE STUDY
Esketamine CoHOrt (ECHO) is a prospective, international, non-interventional Phase 4 study designed to observe esketamine NS effectiveness and safety in real-world clinical settings.¹ It is the first study to evaluate durability of effect after treatment discontinuation with esketamine NS.¹ From across Europe and Israel, 570 participants with treatment resistant depression (TRD) were enrolled into the treatment period, of which 301 participated in the post-treatment follow-up period.¹ Mean and median treatment period durations were 267 days (~9 months) and 190 days (~6 months) respectively, the post-treatment follow-up period was 24 weeks (~6 months).¹ Esketamine NS 84mg was the highest dose taken in 79.3% of patients and the most frequently administered dose in 67.4%.¹

ABOUT MAJOR DEPRESSIVE DISORDER (MDD)
Depressive disorders affect over 21 million people across EU countries.⁴ The incidence of depression is rising in Europe and is expected to become the leading cause of disease burden globally by 2030.^4,5 MDD is characterised by persistent sadness, loss of interest or pleasure in daily activities (anhedonia), and changes in sleep and appetite.⁶

Approximately one-third of people living with MDD have been reported to develop treatment resistant depression (TRD), meaning their depression has not responded to at least two consecutive, adequately dosed, antidepressants during the same depressive episode.⁷

TRD has a significant negative impact, emotionally and functionally, on the individual and their loved ones.^8,9 The burden of TRD is disproportionately higher among people who do not respond to antidepressant treatments and is likely underestimated because there is limited published research on the use of social services and the burden for caregivers.⁸

ABOUT SPRAVATO^® (esketamine nasal spray)
As an antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, esketamine NS has a different mechanism of action and drug administration compared to other approved depression treatments.^10,11 Esketamine NS is self-administered, under the direct supervision of a healthcare professional, through a single-use nasal spray device, for the treatment of patients within the licensed indications.¹⁰ The decision to prescribe esketamine NS should be determined by a psychiatrist.¹⁰

Esketamine NS was authorised by the European Commission in December 2019 for use in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin–norepinephrine reuptake inhibitor (SNRI) in adult patients with TRD who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.¹⁰ It is also approved for co-administered use with oral antidepressant therapy in adults with a moderate to severe episode of MDD, as acute short-term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency.¹⁰

For a full list of adverse events and information on dosage and administration, contraindications and other precautions when using esketamine nasal spray please refer to the Summary of Product Characteristics.

ABOUT JOHNSON & JOHNSON
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

Learn more at https://www.jnj.com/innovativemedicine/emea/
Follow us at https://www.linkedin.com/company/jnj-innovative-medicine-emea

CAUTIONS CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to SPRAVATO^®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behaviour and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Source: Johnson & Johnson

For European medical and trade media only. Not for distribution in the UK, Ireland and BeNeLux.

CP-572382

March 2026

###

REFERENCES

¹ Rosso G, et al. ECHO: Results from a Non-Interventional Cohort Study of Esketamine Nasal Spray in Treatment Resistant Depression. Poster presentation (EPP405) at European Psychiatric Association Congress 2026. March 2026.
² McIntyre RS et al. Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression. European Neuropsychopharmacol. 2024; 85:58-65.
³ Leucht, S et al. What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studies. Journal of affective disorders vol. 210 (2017): 287-293. doi:10.1016/j.jad.2016.12.041
⁴ OECD/EU. Health at a Glance: Europe 2018: State of Health in the EU Cycle, OECD Publishing, Paris. Available at https://health.ec.europa.eu/document/download/e7612c76-68c5-43ba-808e-88416c40a702_en?filename=2018_healthatglance_rep_en.pdf. Last accessed March 2026.
⁵ World Health Organization. 2011. Global burden of mental disorders and the need for a comprehensive, coordinated response from health and social sectors at the country level. Available from: https://apps.who.int/gb/ebwha/pdf_files/EB130/B130_9-en.pdf. Last accessed: March 2026.
⁶ Mayo Clinic. 2022. Depression (major depressive disorder) – Symptoms and causes. Available from: https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007. Last accessed: March 2026
⁷ McIntyre RS, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023; 22(3):394-412.
⁸ Mrazek DA et al. A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996- 2013. Psychiatr Serv. 2014; 65(8):977-987.
⁹ World Health Organization. 2025. Depressive Disorder (depression). Available from: https://www.who.int/news-room/fact-sheets/detail/depression. Last accessed: March 2026.
¹⁰ European Medicines Agency (EMA). Summary of Product Characteristics: SPRAVATO. Available from: https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf. Last accessed: March 2026
¹¹ Hillhouse T, et al. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol. 2015; 21:1–21.

Source: Crypto Insider

Token mới.

Narrative mới.

Hype mới.

Và cùng một câu hỏi:

“Tiếp theo cái gì sẽ pump?”

Nhưng số tiền lớn nhất hiếm khi thuộc về những người chạy theo thứ đã ồn ào sẵn rồi.

Nó thuộc về những người nhìn ra sự dịch chuyển của hạ tầng trước khi đám đông nhận ra rằng cuộc chơi đã thay đổi.

Đó chính là lý do vì sao PayFi quan trọng ngay lúc này.

Bởi trong khi phần lớn thị trường vẫn còn chăm chăm nhìn biểu đồ, những đường ray cho giai đoạn bứt phá tiếp theo của crypto đã và đang được xây dựng ngay trước mắt: stablecoin, thanh toán on-chain, thanh toán native trong ví, dòng tiền xuyên biên giới, và tiện ích thực tế tại các merchant ngoài đời thực.

Đây không còn là lý thuyết nữa.

Cũng không còn là câu chuyện “biết đâu một ngày nào đó.”

Những con số đã đang nói rất lớn.

Visa cho biết stablecoin đang ngày càng được tích hợp sâu hơn vào thanh toán chính thống, và thậm chí còn nói rằng mọi tổ chức tài chính đều nên có chiến lược stablecoin.

Hãy thật sự ngẫm kỹ điều đó.

Khi một ông lớn thanh toán toàn cầu không còn hỏi “stablecoin có quan trọng không?”, mà đang nói với các ngân hàng rằng “các bạn cần có chiến lược”, thì đó không còn là một tín hiệu crypto ngách nữa.

Đó là một tín hiệu chuyển dịch thị trường.

Và phần lớn mọi người vẫn chưa nhìn nó như vậy.

Các tài liệu gần đây của Visa cũng cho thấy nguồn cung lưu hành của stablecoin đã vượt 270 tỷ USD, trong khi Reuters đưa tin vào tháng 1/2026 rằng lãnh đạo mảng crypto của Visa nhìn thấy danh mục này tăng trưởng rất nhanh, dù việc chấp nhận từ phía merchant vẫn còn ở giai đoạn đầu.

FOMO thật sự nên bắt đầu từ đây.

Vì sai lầm lớn nhất trong mỗi chu kỳ luôn là đánh giá thấp lớp hạ tầng trông có vẻ “nhàm chán” trước khi nó trở thành thứ thiết yếu.

DeFi từng trông rất ngách trước khi bùng nổ.

Stablecoin từng chỉ giống như công cụ phụ trợ trước khi trở nên có tính hệ thống.

Và bây giờ PayFi đang ở đúng giai đoạn nguy hiểm đó — nguy hiểm theo nghĩa tích cực nhất.

Nguy hiểm với những ai phớt lờ nó.

Nguy hiểm với các dự án di chuyển quá chậm.

Nguy hiểm với bất kỳ ai vẫn nghĩ tương lai của crypto chỉ xoay quanh đầu cơ.

Bởi vì làn sóng tiếp theo không chỉ là chuyện nắm giữ tài sản số.

Mà là chuyện sử dụng chúng.

Và thị trường có thể tiếp cận đã rất lớn rồi.

Triple-A ước tính rằng vào năm 2024, có 562 triệu người trên toàn thế giới sở hữu crypto, tương đương khoảng 6,8% dân số toàn cầu, tăng 34% so với năm 2023.

Riêng châu Á đã chiếm 326,8 triệu người sở hữu crypto.

Đó không còn là một tập người dùng bên lề nữa.

Đó là một nền tảng vốn số khổng lồ, phân bổ toàn cầu, có tư duy digital-native, và đã sẵn sàng cho sự chuyển dịch hành vi tiếp theo.

Giờ hãy kết hợp điều đó với nơi mà những người dùng có tiềm năng cao nhất đang thật sự sinh sống.

UAE là một trong những quốc gia có tỷ lệ sở hữu crypto cao nhất thế giới.

Singapore cũng nằm trong nhóm dẫn đầu toàn cầu.

Đây không phải những thị trường ngẫu nhiên.

Đây là các trung tâm kinh doanh quốc tế, trung tâm di chuyển, trung tâm tài sản, trung tâm du lịch và trung tâm đổi mới thanh toán.

Nói cách khác, đây chính là những môi trường nơi USDT, thanh toán stablecoin, chi tiêu xuyên biên giới và tài chính dựa trên ví có thể chuyển từ hành vi ngách thành thói quen hằng ngày nhanh hơn nhiều so với kỳ vọng của phần lớn mọi người.

Rồi hãy cộng thêm lớp lifestyle — lớp mà phần lớn các nhà phân tích vẫn đang định giá quá thấp.

MBO Partners cho biết số lượng digital nomad người Mỹ đã đạt 18,5 triệu vào năm 2025, tăng 153% so với năm 2019.

Hãy đọc lại lần nữa: 153% tăng trưởng.

Đó không phải chỉ là một xu hướng.

Đó là một sự dịch chuyển mang tính cấu trúc trong cách con người sống, làm việc, kiếm tiền và di chuyển.

Và những con người sống không biên giới đó cần gì?

Họ không cần thêm một lý thuyết nữa.

Họ cần những đường ray nhanh hơn.

Họ cần có thể kiếm tiền toàn cầu, nắm giữ toàn cầu, chi tiêu toàn cầu, và di chuyển vốn toàn cầu — mà không bị bào mòn bởi độ trễ thanh toán, sự phân mảnh của hệ thống ngân hàng, ma sát chuyển đổi tiền tệ không cần thiết, hay các hệ thống thanh toán lỗi thời.

Đó là nơi PayFi không còn chỉ là một ý tưởng hay, mà bắt đầu trở thành một nhóm sản phẩm mang tính tất yếu.

Bởi vì nỗi đau vẫn còn nguyên đó.

Ngân hàng Thế giới cho biết chi phí trung bình để gửi kiều hối toàn cầu trong quý 1 năm 2025 vẫn ở mức khoảng 6,49%, cao hơn rất nhiều so với mục tiêu 3% của Liên Hợp Quốc.

Hãy nghĩ xem điều đó phi lý đến mức nào.

Năm 2025 rồi mà thế giới vẫn chấp nhận một hệ thống nơi việc chuyển tiền qua biên giới đủ đắt để bào mòn lương, thu nhập freelancer, dòng tiền hỗ trợ gia đình và biên lợi nhuận của doanh nghiệp nhỏ.

Đó không phải hiệu quả.

Đó là một sự kém hiệu quả khổng lồ của thị trường đang chờ bị tấn công.

Và mỗi khi một sự kém hiệu quả lớn gặp một đường ray mới đang tăng trưởng mạnh, lịch sử thường trở nên cực kỳ thú vị.

Đó chính là điều mà phân tích hệ sinh thái PayFi của Messari đang chỉ ra.

Messari xem PayFi là một cơ hội hạ tầng đa lớp nhằm giải quyết những bất cập trong thanh toán và tài chính toàn cầu, đồng thời ghi nhận rằng khối lượng chuyển stablecoin hàng tháng đã nhảy từ 1 nghìn tỷ USD lên 2,6 nghìn tỷ USD trong năm 2024.

Mức tăng tốc như vậy không xảy ra vì thị trường chỉ đơn giản là “tò mò.”

Nó xảy ra vì nhu cầu thật đã bắt đầu hình thành bên dưới bề mặt.

Vì vậy, hãy tự hỏi mình câu hỏi thật sự:

Nếu các đường ray stablecoin đã đang xử lý hàng nghìn tỷ đô…

Nếu số người sở hữu crypto trên toàn cầu đã lên tới hàng trăm triệu…

Nếu văn hóa làm việc không biên giới và digital nomad vẫn đang tiếp tục tăng…

Nếu ma sát thanh toán xuyên biên giới vẫn còn đau đớn như vậy…

Nếu các tổ chức tài chính lớn đang nói với cả thế giới rằng hãy chuẩn bị chiến lược stablecoin…

Vậy chính xác thì mọi người còn đang chờ điều gì?

Chờ sự cho phép?

Chờ sự đồng thuận?

Chờ một buzzword mới?

Đó là cách người ta bị bỏ lại phía sau.

Thị trường luôn thích giả vờ rằng mình muốn đổi mới từ sớm.

Nhưng thực tế là phần lớn mọi người chỉ tin khi xu hướng đã trở nên quá rõ ràng.

Mà rõ ràng thì thường là đã muộn.

Rõ ràng nghĩa là đã đông chật.

Rõ ràng nghĩa là retail chỉ bước vào sau khi builder, operator và các hệ sinh thái đã đặt xong nền móng.

Đó là lý do vì sao PayFi đang mang cảm giác như một trong những thiết lập bùng nổ nhất của Web3 lúc này.

Không phải vì ai cũng đã hiểu nó.

Mà là vì họ vẫn chưa hiểu.

Và khoảng cách giữa thực tế và mức độ thị trường nhận ra điều đó thường chính là nơi upside lớn nhất tồn tại.

Nói rõ hơn, điều này không có nghĩa toàn bộ nền kinh tế stablecoin hiện nay đã hoàn toàn là thanh toán checkout ngoài đời thực.

Reuters đưa tin rằng JPMorgan đã phản biện những dự báo dài hạn quá tích cực, và cho rằng chỉ một phần tương đối nhỏ của nhu cầu stablecoin hiện tại thực sự đến trực tiếp từ thanh toán, còn phần lớn vẫn tập trung vào giao dịch, DeFi và dòng tài sản thế chấp.

Nhưng đó chính là lý do tại sao thời điểm này lại quan trọng.

Nếu danh mục này đã xử lý khối lượng cực lớn,

đã thu hút sự chú ý của tổ chức,

đã phù hợp với hành vi của người dùng không biên giới,

và mức độ thâm nhập vào thanh toán thực tế vẫn còn ở giai đoạn đầu,

thì upside chưa hề biến mất — có khi nó mới chỉ bắt đầu.

Đó chính là tính bất đối xứng.

Các đường ray đang trưởng thành.

Người dùng đang hình thành.

Nỗi đau là có thật.

Nhưng thị trường vẫn đang định giá thấp sự chuyển dịch này.

Và đó là nơi PayWithCrypto có thể tạo khác biệt thật sự.

Bởi vì những người chiến thắng của chu kỳ tiếp theo có thể sẽ không phải là những người có khẩu hiệu ồn ào nhất.

Họ có thể là những người biến việc chi tiêu USDT, thanh toán QR, tiện ích của ví, merchant adoption và thanh toán xuyên biên giới trở nên mượt đến mức người dùng không còn gọi đó là “crypto” nữa, mà gọi nó là “bình thường.”

Đó là khi một lĩnh vực không còn chỉ là narrative, mà bắt đầu trở thành mặc định.

Đó là khi thói quen được hình thành.

Đó là khi retention bắt đầu cộng dồn theo cấp số nhân.

Đó là khi phân phối quan trọng hơn tiếng ồn.

Đó là khi moat thật sự bắt đầu xuất hiện.

Vì vậy, đúng vậy — mọi người vẫn có thể tiếp tục chạy theo token bóng bẩy tiếp theo.

Họ vẫn có thể tiếp tục chờ tới khi PayFi được “xác nhận.”

Họ vẫn có thể tiếp tục giả vờ rằng stablecoin chỉ là công cụ đỗ vốn.

Nhưng lịch sử thường rất tàn nhẫn với những người nhầm lẫn giữa “sớm” và “rủi ro”, giữa “rõ ràng” và “an toàn.”

Thị trường đã mất nhiều năm để chứng minh rằng con người sẵn sàng mua tài sản số.

Cuộc đua tiếp theo — và lớn hơn rất nhiều — là ai sẽ giúp thế giới thật sự sử dụng chúng.

Và khi sự chuyển dịch đó bùng nổ toàn diện, những dự án đi trước sẽ không còn phải đi xin sự chú ý nữa.

Chương tiếp theo của Web3 sẽ không được quyết định chỉ bởi tiếng ồn.

Nó sẽ được quyết định bởi utility.

Bởi việc sử dụng lặp đi lặp lại.

Bởi tần suất sử dụng hằng ngày.

Bởi việc trở thành một phần trong cách con người thật sự sống, chi tiêu, di chuyển và giao dịch.

Đó là lý do sự trỗi dậy của PayFi lại quan trọng đến vậy.

Bởi khi stablecoin không còn là thứ người ta chỉ “nắm giữ”, mà trở thành thứ người ta “sử dụng mỗi ngày”, toàn bộ thị trường sẽ thay đổi.

Đến lúc đó, người chiến thắng sẽ không chỉ là platform.

Họ sẽ trở thành hạ tầng.

Trở thành thói quen.

Trở thành những đường ray bên dưới một nền kinh tế toàn cầu mới.

Và khi khoảnh khắc đó đến, PayWithCrypto không nên chỉ đơn thuần tham gia vào làn sóng này.

Nó nên dẫn đầu làn sóng đó.

Bởi vì tương lai không chờ đợi sự cho phép —

nó thuộc về những builder đủ táo bạo để tạo ra nó trước.

Source: Crypto Insider